Skip to main content
SpringerLink
Log in

Effects of the combined administration of hexarelin, a synthetic peptidyl GH secretagogue, and hCRH on ACTH, cortisol and GH secretion in patients with Cushing’s disease

  • Original Article
  • Published:
Journal of Endocrinological Investigation Aims and scope Submit manuscript

Abstract

Hexarelin (HEX) is a peptidyl GH sec-retagogue (GHS) which markedly stimulates GH release but, like other GHS, possesses also CNS-mediated ACTH- and cortisol-releasing activity. Interestingly, the stimulatory effect of HEX on ACTH and cortisol release is exaggerated and higher than that of hCRH in patients with Cushing’s disease (CD). To further clarify the mechanisms by which HEX stimulates the activity of hypothalamo-pituitary-adrenal (HPA) axis in man, in 6 patients with CD (6 women, 38–68 yr old) and in 7 control subjects (CS, 7 women, 22–29 yr old) we studied the effects of HEX (2.0 ώg/kg iv) and/or hCRH (2.0 ώg/kg iv) on ACTH and cortisol (F) secretion. The GH responses to HEX alone and combined with hCRH were also studied in all subjects. Basal ACTH and F levels in CD were higher than in CS (66.3±5.1 vs 16.5±0.6 pg/ml and 217.8±18.5 vs 134.4±4.6 ώg/l, respectively; p<0.02). In CS, the ACTH and F responses to HEX, evaluated as △AUC (mean±SE: 128.7±39.2 pg*min/ml and 328.5±93.2 ώg*min/l, respectively) were lower, though not significantly, than those after hCRH (375.8±128.4 pg*min/ml and 1714.2±598.0 ώg*min/l, respectively), though the peak ACTH and F responses to both stimuli were similar. The co-administration of HEX and hCRH had an additive effect on both ACTH (1189.6±237.2 pg*min/ml) and F secretion (3452.9±648.6 ώg*min/l). In fact, the ACTH and F responses to HEX+hCRH were significantly higher (p<0.01) than those elicited by single stimuli. In CD, HEX induced ACTH and F responses (3603.8±970.7 pg*min/ml and 10955.9±6184.6 ώg*min/l, respectively) clearly higher (p<0.002) than those in CS. The HEX-induced ACTH and F responses in CD were higher, though not significantly, than those recorded after hCRH (1432.7 ±793.5 pg*min/ml and 4832.7±2146.5 ώg*min/l, respectively). On the other hand, the hCRH-induced ACTH and F responses in CD were similar to those in CS. In CD, the coadministration of HEX and hCRH had an additive effect on ACTH (8035.7±1191.1 pg*min/ml) but not on F (10985.4 ±3900.8 ώg*min/l) secretion. In fact, the ACTH, but not the F response to HEX+hCRH was significantly higher (p<0.02) than that elicited by single stimuli. In conclusion, the present study demonstrates that in patients with Cushing’s disease as well as in subjects control Hexarelin and hCRH have an additive effect on ACTH secretion. Considering that, at least in humans, differently from hCRH, GHS have no interaction with AVP, our present findings further agree with the hypothesis that the ACTH-releasing activity of GHS is, at least partially, independent of CRH-mediated mechanisms.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Bowers C.Y., Veeraragavan K., Sethumadhavan K. Atypical growth hormone releasing peptides. In: Bercu B.B., Walker R.F. (Eds.), Growth hormone II, basic and clinical aspects. Springer-Verlag, New York, 1993, p. 203–222.

    Google Scholar 

  2. Ghigo E., Arvat E., Muccioli G., Camanni F. Growth hormone-releasing peptides. Eur. J. Endocrinol., 136: 445, 1997.

    Article  PubMed  CAS  Google Scholar 

  3. Smith R.G., Van der Ploeg L.X.T., Howard A.D., Feighner S.D., Cheng K., Hickey G.J., Wyvratt M.J., Fisher M.H., Nargund R.P., Patchett A.A. Peptidomimetic regulation of growth hormone secretion. Endocr. Rev., 18: 621, 1997.

    Article  PubMed  CAS  Google Scholar 

  4. Deghenghi R., Boutignon F., Luoni M., Grilli R., Guidi M., Locatelli V. Small peptides as potent releasers of growth hormone. J. Ped. Endocrinol. Metab., 8: 311, 1995.

    Article  CAS  Google Scholar 

  5. Korbonits M., Grossman A.B. Growth hormone-releasing peptide and its analogues. Novel stimuli to growth hormone release. Trends Endocrinol. Metab., 6: 43, 1995.

    Article  PubMed  CAS  Google Scholar 

  6. Codd E.E., Shu A.Y.L., Walker R.F. Binding of a growth hormone releasing hexapeptide to specific hypothalamic and pituitary binding sites. Neuropharmacology, 28: 1139, 1989.

    Article  PubMed  CAS  Google Scholar 

  7. Pong S.S., Chaung L.Y.P., Dean D.C., Nargunt R.P., Patchett A.A., Smith R.G. Identification of a new G-protein-linked receptor for growth hormone secretagogues. Mol. Endocrinol., 10: 57, 1996.

    PubMed  CAS  Google Scholar 

  8. Ong H., McNicoll N., Escher E., Collu R., Deghenghi R., Locatelli V., Ghigo E., Muccioli G., Boghen M., Nillson M.H.L. Identification of a pituitary GHRP receptor subtype by the photoaffinity labeling approach using [125I] p-benzoyl-phenylalanine Hexarelin derivative. Endocrinology, 139: 432, 1998.

    Article  PubMed  CAS  Google Scholar 

  9. Muccioli G, Ghè C., Ghigo M.C., Papotti M., Arvat E., Boghen M.F., Nilsson M.H.L., Deghenghi R., Ong H., Ghigo E. Specific receptors for synthetic GH secretagogues in the human brain and pituitary gland. J. Endocrinol., 157: 99, 1998.

    Article  PubMed  CAS  Google Scholar 

  10. Howard A.D., Feighner S.D., Cully D.F., Arena J.P., Liberator P.A., Rosenblum C.I., Uamelin M., Ureniuk D.I., Palyhe O.C., Anderson J., Paress P.S., Diaz C., Chou N., Liu K.K., McKee K.K., Pong S.S., Cheung L.Y., Elbrecth A., Dashkeviez M., Keavehs R., Rishy M., Siringjhsinghji D.J.S., Dean D.C., Melillo D.G., Patchett A.A., Nergund R., Srillin P.R. A receptor in pituitary and hypothalamus that functions in growth hormone release. Science 273: 974, 1996.

    Article  PubMed  CAS  Google Scholar 

  11. Goth M.I., Lyons C.E., Canny B.Y., Thorner M.O. Pituitary adenylate cyclase activating polypeptide, growth hormone (GH)-releasing peptide and GH-releasing hormone stimulate GH release through distinct pituitary receptors. Endocrinology 130: 939, 1992.

    PubMed  CAS  Google Scholar 

  12. Fairhall K.M., Mynett A., Robinson I.C.A.F. Central effects of growth hormone-releasing hexapeptide (GHRP-6) on growth hormone release are inhibited by central somatostatin action. J. Endocrinol. 144: 555, 1995.

    Article  PubMed  CAS  Google Scholar 

  13. Dickson S.L., Luckman S.M. Induction of c-fos messenger ribonucleic acid in neuropeptide Y and growth hormone (GH)-releasing factor neurons in the rat arcuate nucleus following systemic injection of the GH secretagogue, GH-releasing peptide-6. Endocrinology 138: 771, 1997.

    PubMed  CAS  Google Scholar 

  14. Popovic V., Damjanovic S., Micic D., Djurovic M., Dieguez C., Casanueva F.F. Blocked growth hormone-releasing peptide (GHRP-6)-induced GH secretion and absence of the synergic action of GHRP-6 plus GH-releasing hormone in patients with hypothalamopituitary disconnection: evidence that GHRP-6 main action is exerted at the hy-pothalamic level. J. Clin. Endocrinol. Metab. 80: 942, 1995.

    PubMed  CAS  Google Scholar 

  15. Pombo M., Barreiro J., Penalva A., Peino R., Dieguez C., Casanueva F.F. Absence of growth hormone (GH) secretion after the administration of either GH releasing hormone (GHRH), GH-releasing peptide (GHRP-6), or GHRH plus GHRP-6 in children with neonatal pituitary stalk transection. J. Clin. Endocrinol. Metab. 80: 3180, 1995.

    PubMed  Google Scholar 

  16. Loche S., Cambiaso P., Merola B., Colao A., Feadda A., Imbimbo B.P., Deghenghi R., Lombardi G., Cappa M. The effect of Hexarelin on growth hormone (GH) secretion in patients with GH deficiency. J. Clin. Endocrinol. Metab. 80: 2692, 1995.

    PubMed  CAS  Google Scholar 

  17. Hickey G.J., Drisko J., Faidley T., Chang C., Anderson L., Nicolich S., McGuire L., Riches E., Kripe D., Feeney W., Friscino R., Cunnighan P., Frazier E., Chen H., Leroque P., Smith R.G. Mediation by the central nervous system is critical to the in vivo activity of the GH secretagogue L-692,585. J. Endocrinol. 148: 371, 1996.

    Article  PubMed  CAS  Google Scholar 

  18. De Keyzer Y., Lenne F., Bertagna X. Widespread transcription of the growth hormone-releasing peptide receptor gene in neuroendocrine human tumors. Eur. J. Endocrinol. 137: 715, 1997.

    Article  PubMed  Google Scholar 

  19. Jansson J.O., Svensson J., Bengtsson B.A., Frohman L.A., Ahlmant H., Wangberg B., Nilsson O., Nilsson M. Acromegaly and Cushing’s syndrome due to ec-topic production of GHRH and ACTH by a thymic carcinoid tumour: in vitro responses to GHRH and GHRP-6. Clin. Endocrinol. (Oxf.) 48: 243, 1998.

    Article  CAS  Google Scholar 

  20. Thomas G.B., Fairhall K.M., Robinson I.C.A.F. Activation of the hypothalamo-pituitary-adrenal axis by the growth hormone (GH) secretagogue, GH-releasing peptide-6, in rats. Endocrinology 138: 1585, 1997.

    Article  PubMed  CAS  Google Scholar 

  21. Korbonits M., Trainer P.J., Besser G.M. The effect of an opiate antagonist on the hormonal changes induced by hexarelin. Clin. Endocrinol. (Oxf.) 43: 365, 1995.

    Article  CAS  Google Scholar 

  22. Arvat E., Maccagno B., Ramunni J., Di Vito L., Broglio F., Deghenghi R., Camanni F., Ghigo E. Hexarelin, a synthetic growth-hormone releasing peptide, shows no interaction with corticotropin-re-leasing hormone and vasopressin on adrenocorti-cotropin and cortisol secretion in humans. Neuroendocrinology 66: 432, 1997.

    Article  PubMed  CAS  Google Scholar 

  23. Ghigo E., Arvat E., Ramunni J., Colao A., Gianotti L., Deghenghi R., Lombardi G., Camanni F. Adrenocorticotropin- and cortisol-releasing effect of hexarelin, a synthetic growth hormone-releasing peptide, in normal subjects and patients with Cushing’s syndrome. J. Clin. Endocrinol. Metab. 82: 2439, 1997.

    PubMed  CAS  Google Scholar 

  24. Orth D.N. Corticotropin-releasing hormone in humans. Endocr. Rev. 13: 164, 1992.

    PubMed  CAS  Google Scholar 

  25. Copinschi G., van Onderbergen A., L’hermite-Baleriaux M., Mendel C.M., Caufriez A., Leproult R., Bolognese J.A., De Smet M., Thorner M.O., Van Cauter E. Effects of 7-day treatment with a novel, orally active, growth hormone (GH) secretagogue, MK-677, on 24hour GH profiles, Insulin-like growth factor I, and adrenocortical function in normal young men. J. Clin. Endocrinol. Metab. 81: 2776, 1996.

    PubMed  CAS  Google Scholar 

  26. Jacks T., Hickey G., Judith F., Taylor J., Chen H., Krupa D., Feeney W., Schoen W., Fisher M., Wyratt M., Smith R. Effects of acute and repeated intravenous administration of L-692,585, a novel non-peptidyl growth hormone secretagogue, on plasma growth hormone, IGF-I, ACTH, cortisol, prolactin, insulin, and thyroxine levels in beagles. J. Endocrinol. 143: 399, 1994.

    Article  PubMed  CAS  Google Scholar 

  27. Arvat E., Maccagno B., Ramunni J., Di Vito L., Gianotti L., Broglio F., Benso A., Deghenghi R., Camanni F., Ghigo E. Effects of dexamethasone and alprazolam, a benzo-diazepine, on the stimulatory effect of Hexarelin, a synthetic GHRP, on ACTH, cortisol and GH secretion in humans. Neuroendocrinology, 67: 310, 1998.

    Article  PubMed  CAS  Google Scholar 

  28. Grottoli S., Arvat E., MAccario M., Ramunni J., Procopio M., Gianotti L., Deghenghi R., Ghigo E. Effects of alprazolam, a benzodiazepine, on the ACTH and cortisol response to Hexarelin, a synthetic GHRP, in normal subjects and in obese patients with Cushing’s disease. 8th European Congress on obesity Dublin, 1997. Int. J. Obes., 21: 181 (Abstract) S61, 1997.

    Google Scholar 

  29. Korbonits M., Little J.A., Forling M., Trainer G.M., Besser G.M., Grossman A.B. The effect of growth hormone secretagogues on GHRH and arginine vasopressin release from the rat hypothalamus in vitro. 79th Ann. Meet. Endocr. Soc., Minneapolis, 1997, p. 153.

    Google Scholar 

  30. Arvat E., Maccagno B., Ramunni J., Gianotti L., Di Vito L., Deghenghi R., Camanni F., Ghigo E. Effects of histaminergic antagonists on the GH-releasing activity of GHRH or hexarelin, a synthetic hexapeptide, in man. J. Endocrinol. Invest. 20: 122, 1997.

    Article  PubMed  CAS  Google Scholar 

  31. Di Vito L., Arvat E., Gianotti L., Broglio F., Sortino G., Lanfranco F., Deghenghi R., Ghigo E. Influence of galanin and serotonin on the GH, PRL, ACTH and cortisol response to Hexarelin, a synthetic GHRP, in humans. Ann. Endocr, 58: 86 (Abstract) P1–6, 1997.

    Google Scholar 

  32. Barlier A., Gunz G., Morange-Ramos I., Dufour H., Jaquet P., Enjalbert A. Functional expression of growth hormone secreta-gogue receptors (GHS-R) in human pituitary adenomas. 5th international Pituitary Congress, 1998. Abstract book p. 60.

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Divisione di Endocrinologia, Dipartimento di Medicina Interna, Università di Torino, C.so Dogliotti 14, 10126, Torino, Italy

    E. Arvat, J. Ramunni, R. Giordano, B. Maccagno, F. Broglio, A. Benso & E. Ghigo M.D.

  2. Europeptides, Argenteuil, France

    R. Deghenghi

Authors
  1. E. Arvat
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. J. Ramunni
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. R. Giordano
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. B. Maccagno
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. F. Broglio
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. A. Benso
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. R. Deghenghi
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. E. Ghigo M.D.
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Arvat, E., Ramunni, J., Giordano, R. et al. Effects of the combined administration of hexarelin, a synthetic peptidyl GH secretagogue, and hCRH on ACTH, cortisol and GH secretion in patients with Cushing’s disease. J Endocrinol Invest 22, 23–28 (1999). https://doi.org/10.1007/BF03345474

Download citation

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF03345474

Key-words

Search

Navigation